Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Formulary Guidelines Back In Spotlight With Essential Health Benefits Proposal

Executive Summary

HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.

You may also be interested in...



USP Draft Medicare Formulary Update Adds Nine Classes, Targeted Cancer Drugs

Released Oct. 1, the draft update to the USP Medicare Model Formulary Guidelines includes several new classes formed to accommodate novel therapies approved in the last three years, including targeted cancer drugs.

USP’s Draft Revisions To Medicare Formulary Guidelines Coming In September

In addition to their use as a reference for Medicare Part D plans, the current guidelines serve as a benchmark for evaluating the formularies of private insurance plans offered through state exchanges.

HHS Essential Health Benefits Drug Coverage Provisions Unchanged In Final Rule

Although the rule does not adopt the many drug access protections requested by drug industry stakeholders, it does promise forthcoming guidance regarding HHS expectations for the formulary exceptions process that should be followed by exchange plans.

Related Content

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel